Work

Supplemental Table 2 from Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma

Year: 2023

Type: supplementary-materials

Abstract: Individual drug characteristics and doses, maximum plasma levels and protein binding of panobinostat and belinostat in the two phase 1 studies

DOI: 10.1158/1535-7163.22504716.v1

Authors: Sumati Gupta, Daniel J. Albertson, Timothy J. Parnell, Andrew Butterfield, Alexis Weston, Lisa M. Pappas, Brian Dalley, John M. O’Shea, William T. Lowrance, Bradley R. Cairns, Joshua D. Schiffman, Sunil Sharma

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362622647

Cites:

Cited by:

Related to: 10